Carbamazepine and false positive dexamethasone suppression tests for Cushing's syndrome

Ronald C W Ma, Wing Bun Chan, Wing Yee So, Peter C Y Tong, Juliana C N Chan and Chun Chung Chow

BMJ 2005;330:299-300
doi:10.1136/bmj.330.7486.299

Updated information and services can be found at:
http://bmj.com/cgi/content/full/330/7486/299

References
This article cites 15 articles, 7 of which can be accessed free at:
http://bmj.com/cgi/content/full/330/7486/299#BIBL

Rapid responses
One rapid response has been posted to this article, which you can access for free at:
http://bmj.com/cgi/content/full/330/7486/299#responses
You can respond to this article at:
http://bmj.com/cgi/eletter-submit/330/7486/299

Email alerting service
Receive free email alerts when new articles cite this article - sign up in the box at the top left of the article

Topic collections
Articles on similar topics can be found in the following collections

Other Endocrinology (624 articles)
Pharmacology and toxicology (372 articles)
Drugs: endocrine system (133 articles)

Notes
tory for low resource settings, including further research on developing simple, acceptable, and low cost approaches for sterilisation and reuse of cautery tips.

The experts also discussed programmatic research, including prospective evaluations of different techniques, studies to determine the feasibility of implementing and training providers on various techniques, and research to identify practical differences between the techniques and perhaps to make recommendations for providers depending on the number of vasectomies done in a particular clinical setting. Future research should clarify the appropriate use of cautery and fascial interposition in low resource settings.

We thank John M Pile of EngenderHealth, Tim Black of Marie Stopes International, and Michel Labrecque of Laval University for careful review of this document. We also thank the clinicians who participated in the vasectomy studies we cited and the participants in both expert consultations on vasectomy, whose leadership and vision were invaluables in developing the points of consensus shared here.

Contributors: KWA and KB wrote the text. DCS developed the concept of the article, provided editorial input, and is the guarantor.

Funding: Partial support for this work was provided by EngenderHealth with funds from the US Agency for International Development (USAID) Cooperative Agreements No HRN-A-00-98-00042-00 and No GPO-A-00-03-00006-00, and by Family Health International with funds from USAID Cooperative Agreement No CCP-A-00-95-00022-02. The views expressed in the article are those of the authors and do not necessarily reflect those of EngenderHealth, Family Health International, or USAID.

Competing interests: None declared.


Lesson of the week

Carbamazepine and false positive dexamethasone suppression tests for Cushing's syndrome

Ronald C W Ma, Wing Bun Chan, Wing Yee So, Peter C Y Tong, Juliana C N Chan, Chun Chung Chow

The clinical features of Cushing's syndrome may be subtle to begin with, and they resemble those of patients with metabolic syndrome. The key to diagnosing Cushing's syndrome is a high index of suspicion and the use of screening tests. The 1 mg overnight dexamethasone suppression test is commonly used. Subsequent biochemical evaluation often uses higher doses of dexamethasone. The overnight dexamethasone suppression test is also increasingly used in the functional evaluation of incidental adrenal masses.

We describe two patients, both of whom were suspected of having Cushing's syndrome based on abnormal results from overnight dexamethasone suppression tests. Subsequent evaluation excluded Cushing's syndrome in both patients. The false positive suppression tests were because of accelerated metabolism of dexamethasone caused by carbamazepine. Awareness of this potential pitfall in the diagnosis of Cushing's syndrome is important to avoid unnecessary investigations and anxiety.

Case reports

Case 1

A 24 year old woman was referred to the clinic for investigation of her weight gain. She had noticed progressive weight gain in recent years. She had a known history of depression, for which she has been prescribed alprazolam, sertraline, and propranolol. She had no history of steroid use. She was a non-smoker and was teetotal. On examination, she was...
obese with a round face and moderate facial acne. She was normotensive. Serum electrolytes were normal.

We suspected her as possibly having Cushing’s syndrome and arranged a 1 mg overnight dexamethasone suppression test. This showed failure of suppression with a cortisol concentration of 256 nmol/l (normal < 50 nmol/l) after the dexamethasone. We were subsequently admitted to hospital for further investigations, and we did a low dose dexamethasone suppression test. This showed failure of suppression on low dose dexamethasone (baseline serum cortisol 269 nmol/l, cortisol 294 nmol/l after dexamethasone 0.5 mg every six hours for 48 hours). Baseline adrenocorticotropic hormone was low (< 2.2 ng/l).

We made a provisional diagnosis of Cushing’s syndrome and arranged imaging studies. Computed tomography of her abdomen showed normal adrenal glands. We later found out that she had been taking, for temporal lobe epilepsy, 400 mg carbamazepine three times a day, which may have interfered with her biochemical tests. A 24 hour collection of urine for free cortisol, measured by radioimmunoassay, was normal. Further investigations showed normal daily variation in cortisol concentration, with a low midnight cortisol concentration of 7 nmol/l (normal < 50 nmol/l) and 503 nmol/l in the morning. We decided that she did not have any clinical evidence of Cushing’s syndrome and that her failed dexamethasone suppression tests were due to the effect of carbamazepine inducing the metabolism of dexamethasone. She was last seen in May 2004 and was well with stable body weight.

Case 2
A 52 year old woman with a history of type 2 diabetes and hypertension was referred to the clinic for management of her diabetes. She did not smoke and did not drink alcohol regularly. She was overweight, and we arranged an overnight dexamethasone suppression test. This showed failure of suppression with a cortisol concentration of 149 nmol/l (normal < 50 nmol/l) after giving 1 mg dexamethasone. We initially suspected that she had Cushing’s syndrome. Further questioning found that she had trigeminal neuralgia, for which she has been taking carbamazepine 400 mg three times a day for a year. After discussion with her neurologist, we took her off carbamazepine and switched her to amitriptyline. An overnight dexamethasone suppression test repeated three weeks later was normal, with a cortisol concentration of 19 nmol/l after suppression.

Discussion
Cushing’s syndrome arises from excess production of cortisol and has a high mortality if left untreated. The overnight 1 mg dexamethasone suppression test is designed to assess the ability of exogenous dexamethasone to suppress endogenous corticosteroid and hence cortisol production. Dexamethasone is primarily metabolised by the cytochrome P450 system, by hepatic CYP3A4, an enzyme complex responsible for the metabolism of many xenobiotics. Considerable increases in cytochrome P450 enzymes can be seen in regular smokers and people who drink alcohol regularly. Several drugs such as phenobarbitol, primidone, ethosuximide, carbamazepine, and rifampicin induce the activity of CYP3A4, and can lead to false positive dexamethasone suppression tests. Conversely, patients with adrenal insufficiency and taking steroid replacement may need increased doses of steroids if also taking these enzyme inducers.

During endocrine testing, patients should ideally stop taking these interacting drugs. If this is not feasible, alternative investigations for evaluation include use of midnight cortisol, late night salivary cortisol, or hydrocortisone suppression tests. Measurement of urinary free cortisol may be helpful, although carbamazepine has also been reported to interfere with urinary cortisol measurements by high performance liquid chromatography. In screening patients for Cushing’s syndrome, be aware of potential drug interactions with dexamethasone, which may lead to false positive results. Appropriate investigations and interpretation of results is necessary to avoid misdiagnosing Cushing’s syndrome.

Contributors: RCWM collected the cases and initiated the project. All authors were actively involved with the care of the patients and participated in writing and critically reviewing the manuscript. RCWM is guarantor.

Funding: None.

Competing interests: None declared.


(Accepted 28 September 2004)